ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Not Recruiting

Trial ID: NCT01777152


This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Official Title

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Stanford Investigator(s)

Ranjana Advani
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma

Lauren Maeda
Lauren Maeda

Clinical Associate Professor, Medicine - Oncology

Hans-Christoph Becker, MD, FSABI, FSCCT

Clinical Professor, Radiology


Inclusion Criteria:

   - Patients with newly diagnosed, CD30-positive mature T-cell lymphomas

   - Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm
   by CT

   - Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

Exclusion Criteria:

   - History of another primary invasive malignancy that has not been in remission for at
   least 3 years

   - Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative
   disorders and lymphomas or mycosis fungoides

   - History of progressive multifocal leukoencephalopathy (PML)

   - Cerebral/meningeal disease related to the underlying malignancy


drug: cyclophosphamide

drug: doxorubicin

drug: vincristine

drug: prednisone

drug: brentuximab vedotin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.